|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 71.3 TWD | +0.28% |
|
+1.28% | -5.69% |
| May. 14 | Polaris Group Announces Change of the Member of Compensation Committee | CI |
| 2023 | Polaris Group Announces the Appointment of K Evin Wu | CI |
Polaris Group announced the approval of phase 3 clinical protocol treating Hepatocellular Carcinoma (HCC) with ADI-PEG 20. This is a randomized, double-blinded, multi-center trial, and approximately 300 participants will be randomized in the study. The primary endpoint is OS with PFS as a secondary endpoint.
Polaris Group will keep promote the clinical application of ADI-PEG 20.
| 1st Jan change | Capi. | |
|---|---|---|
| -5.69% | 1.63B | |
| +28.90% | 49.18B | |
| +0.91% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.44% | 26.09B | |
| -22.64% | 18.71B | |
| +8.16% | 13.26B | |
| +32.17% | 12.32B | |
| -0.40% | 11.99B |
POLARIS GROUP 
